Passage Bio to merge with Remix Therapeutics in $226 million all-stock deal
Passage Bio, Inc. has agreed to merge with Remix Therapeutics, Inc., with Remix's shareholders receiving shares of Passage common stock based on a formula…
$226M$20M
Company
SEC filing news and material events for Passage BIO, Inc., briefed from primary-source filings.
1 story
Passage Bio, Inc. has agreed to merge with Remix Therapeutics, Inc., with Remix's shareholders receiving shares of Passage common stock based on a formula…